P21
Also known as: P021, Cntf small-molecule peptidomimetic
By GLPeptideSciences Editorial Team · How we evaluate evidence · Reviewed by Dr. George S. Watson, MD, Cardiothoracic Surgeon · Updated 2026-06-02
A peptidomimetic derived from a region of ciliary neurotrophic factor (CNTF), studied in animal models for neurogenesis and neuroprotection.
What it is & how it works
What it is
P21 is a peptidomimetic based on an active region of ciliary neurotrophic factor (CNTF), designed to capture neurotrophic activity in a smaller, more drug-like molecule.
How it is thought to work
In animal models it’s associated with promoting neurogenesis (new neuron formation) and supporting neuronal survival, mainly studied in the context of cognitive decline.
The evidence and the caveat
The results are confined to animal models. There’s no human trial data, so any confident claim about cognitive benefit or safety in people is unsupported.
What it's discussed & studied for
- Neurogenesis and cognition (preclinical)
- Neuroprotection discussion
Discussion of a use is not a claim that it works or is approved.
Research status
Preclinical. Promising in rodent models of cognitive decline; no human trial data. Not approved.
Evidence quality
Interesting animal results, no human validation. Treat claims as preclinical.
Dosing discussion
No human protocol exists; anything circulating is extrapolated from animal studies.
Educational summary of what is discussed in the literature and community — not a dosing recommendation or medical advice.
Safety & harm reduction
Human safety is uncharacterized. Limited animal data does not establish human safety.
Sourcing literacy
No approved product; research-market material is unverified.
Selected literature
FAQ
Has P21 been tested in humans?
No. The supportive work is in animal models; it has not been validated in human trials and is not approved.